RxDoctor Payments Data

Andrew King, MD

Obstetrics & Gynecology · Toms River, NJNPI 1164515953

Payments from drug & device makers

$331in general payments, 2019–2025

Across 19 payments — averaging $17.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Indivior Inc.$192
  • Orexo US, Inc.$109
  • Viiv Healthcare Company$17
  • Braeburn Inc.$14
$150in research payments, 2019–2025

Across 1 payment — averaging $150.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Indivior Inc.$150

What the payments were for

  • Food & beverage$331100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$331 in reported general payments places this provider in the 35th percentile of 1,242 obstetrics & gynecology providers in New Jersey.

See all obstetrics & gynecology providers in New Jersey

Medicare billing

Part B allowed, 2024
$121,942
Medicare patients
633
Services billed
1,849

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ZubsolvBuprenorphine Hcl/Naloxone Hcl32$24,867
SuboxoneBuprenorphine Hcl/Naloxone Hcl29$23,859
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl141$20,172
Buprenorphine Hcl31$536
Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip14$277
Zolpidem Tartrate15$109
Amoxicillin11$77

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Orexo US, Inc.Zubsolv$109$24,86732 claims
Indivior Inc.Suboxone$192$23,85929 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 1,242 obstetrics & gynecology providers in New Jersey.

Other obstetrics & gynecology in Toms River

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →